Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research note published on Tuesday. The firm issued a sell rating on the stock.

Oragenics Price Performance

Shares of Oragenics stock opened at $0.33 on Tuesday. The company’s 50 day moving average price is $0.34 and its two-hundred day moving average price is $0.65. The firm has a market capitalization of $4.07 million, a P/E ratio of -0.05 and a beta of 0.40. Oragenics has a fifty-two week low of $0.25 and a fifty-two week high of $6.42.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.